Tumor-selective adenoviral-mediated GFP genetic labeling of human cancer in the live mouse reports future recurrence after resection

Hiroyuki Kishimoto, Ryoichi Aki, Yasuo Urata, Michael Bouvet, Masashi Momiyama, Noriaki Tanaka, Toshiyoshi Fujiwara, Robert M. Hoffman

Research output: Contribution to journalArticle

63 Citations (Scopus)

Abstract

We have previously developed a telomerase-specific replicating adenovirus expressing GFP (OBP-401), which can selectively label tumors in vivo with GFP. Intraperitoneal (i.p.) injection of OBP-401 specifically labeled peritoneal tumors with GFP, enabling fluorescence visualization of the disseminated disease and real-time fluorescence surgical navigation. However, technical problems of removing all cancer cells still remain, even with fluorescence-guided surgery. In this study, we report that in vivo OBP-401 labeling of tumors with GFP before fluorescence-guided surgery reports cancer recurrence after surgery. Recurrent tumor nodules brightly expressed GFP, indicating that initial OBP-401-GFP labeling of peritoneal disease was genetically stable such that proliferating residual cancer cells still express GFP. In situ tumor labeling with a genetic reporter has important advantages over antibody and other non-genetic labeling of tumors, since residual disease remains labeled during recurrence and can be further resected under fluorescence guidance.

Original languageEnglish
Pages (from-to)2737-2741
Number of pages5
JournalCell Cycle
Volume10
Issue number16
DOIs
Publication statusPublished - Aug 15 2011

Fingerprint

Medical Genetics
Recurrence
Fluorescence
Neoplasms
Residual Neoplasm
Peritoneal Diseases
Telomerase
Intraperitoneal Injections
Adenoviridae
Antibodies

Keywords

  • Adenovirus
  • Cancer labeling
  • Detection
  • Fluorescence-guided surgery
  • Green fluorescent protein
  • In situ
  • Recurrence

ASJC Scopus subject areas

  • Cell Biology
  • Molecular Biology
  • Developmental Biology

Cite this

Tumor-selective adenoviral-mediated GFP genetic labeling of human cancer in the live mouse reports future recurrence after resection. / Kishimoto, Hiroyuki; Aki, Ryoichi; Urata, Yasuo; Bouvet, Michael; Momiyama, Masashi; Tanaka, Noriaki; Fujiwara, Toshiyoshi; Hoffman, Robert M.

In: Cell Cycle, Vol. 10, No. 16, 15.08.2011, p. 2737-2741.

Research output: Contribution to journalArticle

Kishimoto, Hiroyuki ; Aki, Ryoichi ; Urata, Yasuo ; Bouvet, Michael ; Momiyama, Masashi ; Tanaka, Noriaki ; Fujiwara, Toshiyoshi ; Hoffman, Robert M. / Tumor-selective adenoviral-mediated GFP genetic labeling of human cancer in the live mouse reports future recurrence after resection. In: Cell Cycle. 2011 ; Vol. 10, No. 16. pp. 2737-2741.
@article{c5164f6a2a0840a184a87132b77e0e10,
title = "Tumor-selective adenoviral-mediated GFP genetic labeling of human cancer in the live mouse reports future recurrence after resection",
abstract = "We have previously developed a telomerase-specific replicating adenovirus expressing GFP (OBP-401), which can selectively label tumors in vivo with GFP. Intraperitoneal (i.p.) injection of OBP-401 specifically labeled peritoneal tumors with GFP, enabling fluorescence visualization of the disseminated disease and real-time fluorescence surgical navigation. However, technical problems of removing all cancer cells still remain, even with fluorescence-guided surgery. In this study, we report that in vivo OBP-401 labeling of tumors with GFP before fluorescence-guided surgery reports cancer recurrence after surgery. Recurrent tumor nodules brightly expressed GFP, indicating that initial OBP-401-GFP labeling of peritoneal disease was genetically stable such that proliferating residual cancer cells still express GFP. In situ tumor labeling with a genetic reporter has important advantages over antibody and other non-genetic labeling of tumors, since residual disease remains labeled during recurrence and can be further resected under fluorescence guidance.",
keywords = "Adenovirus, Cancer labeling, Detection, Fluorescence-guided surgery, Green fluorescent protein, In situ, Recurrence",
author = "Hiroyuki Kishimoto and Ryoichi Aki and Yasuo Urata and Michael Bouvet and Masashi Momiyama and Noriaki Tanaka and Toshiyoshi Fujiwara and Hoffman, {Robert M.}",
year = "2011",
month = "8",
day = "15",
doi = "10.4161/cc.10.16.16756",
language = "English",
volume = "10",
pages = "2737--2741",
journal = "Cell Cycle",
issn = "1538-4101",
publisher = "Landes Bioscience",
number = "16",

}

TY - JOUR

T1 - Tumor-selective adenoviral-mediated GFP genetic labeling of human cancer in the live mouse reports future recurrence after resection

AU - Kishimoto, Hiroyuki

AU - Aki, Ryoichi

AU - Urata, Yasuo

AU - Bouvet, Michael

AU - Momiyama, Masashi

AU - Tanaka, Noriaki

AU - Fujiwara, Toshiyoshi

AU - Hoffman, Robert M.

PY - 2011/8/15

Y1 - 2011/8/15

N2 - We have previously developed a telomerase-specific replicating adenovirus expressing GFP (OBP-401), which can selectively label tumors in vivo with GFP. Intraperitoneal (i.p.) injection of OBP-401 specifically labeled peritoneal tumors with GFP, enabling fluorescence visualization of the disseminated disease and real-time fluorescence surgical navigation. However, technical problems of removing all cancer cells still remain, even with fluorescence-guided surgery. In this study, we report that in vivo OBP-401 labeling of tumors with GFP before fluorescence-guided surgery reports cancer recurrence after surgery. Recurrent tumor nodules brightly expressed GFP, indicating that initial OBP-401-GFP labeling of peritoneal disease was genetically stable such that proliferating residual cancer cells still express GFP. In situ tumor labeling with a genetic reporter has important advantages over antibody and other non-genetic labeling of tumors, since residual disease remains labeled during recurrence and can be further resected under fluorescence guidance.

AB - We have previously developed a telomerase-specific replicating adenovirus expressing GFP (OBP-401), which can selectively label tumors in vivo with GFP. Intraperitoneal (i.p.) injection of OBP-401 specifically labeled peritoneal tumors with GFP, enabling fluorescence visualization of the disseminated disease and real-time fluorescence surgical navigation. However, technical problems of removing all cancer cells still remain, even with fluorescence-guided surgery. In this study, we report that in vivo OBP-401 labeling of tumors with GFP before fluorescence-guided surgery reports cancer recurrence after surgery. Recurrent tumor nodules brightly expressed GFP, indicating that initial OBP-401-GFP labeling of peritoneal disease was genetically stable such that proliferating residual cancer cells still express GFP. In situ tumor labeling with a genetic reporter has important advantages over antibody and other non-genetic labeling of tumors, since residual disease remains labeled during recurrence and can be further resected under fluorescence guidance.

KW - Adenovirus

KW - Cancer labeling

KW - Detection

KW - Fluorescence-guided surgery

KW - Green fluorescent protein

KW - In situ

KW - Recurrence

UR - http://www.scopus.com/inward/record.url?scp=80051710716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051710716&partnerID=8YFLogxK

U2 - 10.4161/cc.10.16.16756

DO - 10.4161/cc.10.16.16756

M3 - Article

VL - 10

SP - 2737

EP - 2741

JO - Cell Cycle

JF - Cell Cycle

SN - 1538-4101

IS - 16

ER -